Today: 20 May 2026
Unilever PLC stock rises into the weekend as investors eye U.S. CPI and Feb results
11 January 2026
1 min read

Unilever PLC stock rises into the weekend as investors eye U.S. CPI and Feb results

London, Jan 11, 2026, 08:36 GMT — Market closed

  • Unilever gained 1.7% on Friday, buoyed by a wider rally in London stocks following the U.S. jobs report.
  • The stock is still far from its 52-week peak, as investors balance expectations of rate cuts against concerns over growth and margin performance.
  • Upcoming triggers to watch: U.S. inflation figures on Jan. 13 and Unilever’s full-year earnings on Feb. 12.

Unilever PLC’s shares closed up 1.7% at 4,744 pence on Friday, finishing the week stronger. With the London market closed Sunday, trading resumes Monday amid renewed focus on macroeconomic data and interest rates.

This move takes on added weight as Unilever approaches its full-year results next month, with investors keen to understand the business after shedding its ice cream division. The company will announce its fourth-quarter and full-year 2025 figures on Feb. 12.

The FTSE 100 hit a record closing high on Friday, boosted by a U.S. jobs report that kept hopes alive for Federal Reserve rate cuts ahead. Traders currently price in roughly 54 basis points of easing for the year — a basis point equals one-hundredth of a percentage point — according to LSEG data referenced by Reuters.

The rate picture remains unsettled. “A likely ‘hot’ inflation print next week suggests no action before March,” James Knightley, chief international economist at ING, said Friday. Reuters

Unilever’s stock technically has wiggle room in either direction. Its 52-week range spans about 4,610 pence to 5,542 pence. Friday’s close landed below the upper end of that bracket and hovered close to recent lows.

The portfolio saw a recent update. Unilever carried out an 8-for-9 share consolidation after spinning off its ice cream arm, Magnum, last December. The goal: streamline its focus on household and personal care brands.

Chief executive Fernando Fernandez described the next phase as sharper and more primed for deals. Back in December, he revealed the group plans to spend roughly 1.5 billion euros annually on mergers and acquisitions, focusing mainly on the U.S. He also projected a second-half operating margin of no less than 19.5% following the separation.

In February, traders will focus on whether growth comes from volume or price. Operating margin — the portion of sales retained as profit — will also be under scrutiny. Investors will seek updates on the group’s plans for cash deployment post spin-off, such as bolt-on acquisitions or buybacks.

Ahead of that, all eyes turn to the U.S. consumer price index for December 2025, set for release Tuesday, Jan. 13. This report could swiftly shift global rate expectations—and with them, valuations for steady consumer stocks like Unilever.

The path isn’t smooth. Any drop in consumer demand, a rise in input costs, or currency shifts hitting the group’s emerging-market profits could quickly sour investor confidence in bold margin forecasts.

Stock Market Today

  • Top 5 Big Data Stocks to Watch as Wall Street Advances
    May 20, 2026, 9:35 AM EDT. Big Data companies process and analyze vast diverse datasets, fueling tech growth on Wall Street. Key players include Cisco Systems (CSCO), Salesforce (CRM), Palantir (PLTR), Cloudflare (NET), and Datadog (DDOG), all rated Zacks Rank #2 (Buy). Cisco leads with record revenues driven by strong AI-driven data center orders, projecting a 4.5x rise in AI infrastructure sales by fiscal 2026 while cutting 4,000 jobs to focus on AI and security. Salesforce accelerates investments in generative AI with its Einstein GPT platform and a venture fund targeting AI innovation, especially in Europe. These stocks exemplify the sector's growth potential amid the ongoing tech rally.

Latest articles

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio’s FDA Deadline Could Change Its Bladder-Cancer Story—But the Risk Is Still There

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
AmpliTech Jumps After 5G Approval Clears North America Sales Path

AmpliTech Jumps After 5G Approval Clears North America Sales Path

20 May 2026
AmpliTech received U.S. and Canadian certification for its full indoor 5G Native DAS hardware, enabling immediate commercial sales and integration across North America. Shares rose about 14% in premarket trading after the announcement. The company said it has orders from a North American mobile network operator, with shipments set to begin later this year.
Intuit’s Q3 Numbers Land as Shares Down 39%

Intuit’s Q3 Numbers Land as Shares Down 39%

20 May 2026
Intuit will report fiscal third-quarter results after U.S. markets close Wednesday, following a 39% stock drop over the past year. Analysts expect earnings of $12.57 per share on $8.54 billion revenue, both up from last year. The quarter covers peak tax season for TurboTax and QuickBooks. Intuit shares closed at $399.71 Tuesday, down 0.9%.
PLS Group Limited stock: What to watch before ASX reopens after Friday dip
Previous Story

PLS Group Limited stock: What to watch before ASX reopens after Friday dip

BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results
Next Story

BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results

Go toTop